Form 4 for CUE Cue Biopharma, Inc.
Accepted 2022-04-04 00:00:00 ET · period of report 2022-03-31 · accession 0001209191-22-022568 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-04-04 | 2022-03-31 | CUE | Fletcher Aaron G.L. | Dir | P - Purchase | $4.76 | +735.0K | 735.0K | New | +$3.50M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-31 | P | A | 735,000 | $4.76 | 735,000 | I See footnote | — | — | (F1) The reported shares were purchased, and are owned, directly by Bios Special Opportunity Fund, LP. Aaron Fletcher is the manager of Bios Advisors GP, LLC, the general partner of Bios Capital Management, L.P., the general partner of Bios Equity SOF I, LP, the general partner of Bios Special Opportunity Fund, LP. |